What is the translation of " DECREASE IN HAEMOGLOBIN " in Slovenian?

• znižanje hemoglobina
• zmanjšanje hemoglobina
• znižanje hemoglobina)a

Examples of using Decrease in haemoglobin in English and their translations into Slovenian

Decrease in haemoglobin in your blood.
Zmanjšanje hemoglobina v krvi.

TIMI Minor Bleed: Clinically apparent with 30 50 g/l decrease in haemoglobin.
Blaga krvavitev po TIMI: Klinično opazna z znižanjem hemoglobina 30-50 g/l.

G/dL decrease in haemoglobin during any.
G/dl znižanje hemoglobina v katerem koli.

Medicinaltreated with irbesartan, a decrease in haemoglobin*, which was not.
Boleznijo, ki so jih zdravili z irbesartanom, so opazili znižanje hemoglobina*, ki ni.

Decrease in haemoglobin and in haematocrit.
Znižana vrednost hemoglobina in hematokrita.

None of these changes were associated with bleeding episodes or a decrease in haemoglobin.
Te spremembe niso bile povezane z epizodami krvavitev ali znižanjem hemoglobina.

Anaemia(decrease in haemoglobin)a, b, Lymphopaenia.
Anemija(znižanje hemoglobina)a, b, limfocitopenija.

That treatment with Volibris often causes a decrease in haemoglobin and haematocrit.
Da zdravljenje z zdravilom Volibris pogosto povzroči znižanje hemoglobina in hematokrita.

Decrease in haemoglobin in your blood(low red blood cell count).
Znižanje hemoglobina v krvi(nizko število rdečih krvnih celic).

That treatment with Volibris often causes a decrease in haemoglobin and haematocrit.
Da je zdravljenje z zdravilom Volibris pogosto povezano z znižanjem vrednosti hemoglobina in hematokrita.

Anaemia(decrease in haemoglobin)a, b, Neutropaenia decrease in absolute.
Anemija(znižanje hemoglobina)a, b, nevtropenija zmanjšanje absolutnega.

TIMI Major Bleed: Clinically apparent withgt; 50 g/L decrease in haemoglobin or intracranial haemorrhage.
Huda krvavitev po TIMI: Klinično opazna z znižanjem hemoglobinagt; 50 g/l ali intrakranialna krvavitev.

Decrease in haemoglobin, Decrease in haematocrit, Neutropenia, Thrombocytopenia.
Znižana koncentracija hemoglobina, zmanjšanje hematokrita, nevtropenija, trombocitopenija.

Macitentan may lead to more reduction of blood pressure and decrease in haemoglobin in patients with kidney problems.
Macitentan lahko povzroči znižanje krvnega tlaka in znižanje ravni hemoglobina pri bolnikih s težavami z ledvicami.

Decrease in haemoglobin in your blood increased fatty acids(triglycerides), bilirubin or lipase in the blood.
Zmanjšanje hemoglobina v krvi zvišanje maščobnih kislin(trigliceridov), bilirubina ali sladkorja v krvi.

Major Other: Clinically apparent with 30 50 g/L decrease in haemoglobin or 2-3 red cell units transfused; or significantly disabling.
Hude druge: Klinično opazna z znižanjem hemoglobina 30-50 g/l ali transfuzijo 2-3 enot eritrocitov, ali povzroči pomembno okvaro.

A decrease in haemoglobin, which was not clinically significant, has been observed in 1.7%(i. e. common) of hypertensive patients with advanced diabetic renal disease treated with irbesartan.
Znižanje hemoglobina, ki ni bilo klinično pomembno, so opazili pri 1, 7% bolnikov(to je pogosto) z visokim krvnim tlakom z napredovalo diabetično ledvično boleznijo, ki so jih zdravili z irbesartanom.

PLATO Major Other: Significantly disabling, OR clinically apparent with 30-50 g/L decrease in haemoglobin, OR 2-3 red cell units transfused.
Druge hude po PLATO: Pomembna, onesposabljajoča ALI klinično opazna z znižanjem hemoglobina 30-50 g/l ALI transfuzijo 2-3 enot eritrocitov.

That treatment with Tracleer is associated with a decrease in haemoglobin. o Need for blood monitoring Prior to initiation of treatment Monthly during the first 4 months Quarterly thereafter.
Da je zdravljenje z zdravilom Tracleer povezano z znižanjem hemoglobina potrebno je spremljati kri o pred začetkom zdravljenja prve 4 mesece mesečno po tem vsako četrtletje.

PLATO Major Fatal/life-threatening: Fatal bleeding, OR any intracranial bleeding, OR intrapericardial with cardiac tamponade, OR with hypovolaemic shock or severe hypotension requiring pressors/inotropes or surgery OR clinically apparent withgt; 50 g/L decrease in haemoglobin or≥4 red cell units transfused.
Hude smrtne/smrtno nevarne po PLATO: Krvavitev s smrtnim izidom ALI katera koli intrakranialna krvavitev ALI intraperikardialna krvavitev s tamponado srca ALI hipovolemični šok ali huda hipotenzija, ki zahteva presorska/inotropna zdravila ali operacijo ALI klinično opazna z znižanjem hemoglobina zagt; 50 g/l ali transfuzijo ≥ 4 enot eritrocitov.

Dry mouth low white blood cell and/or platelet count, decrease in haemoglobin in your blood, increase in triglycerides, lipase and/or bilirubin in your blood.
Uha usta zmanjšano število belih krvničk in/ali trombocitov, zmanjšana koncentracija hemoglobina v krvi, povečana koncentracija trigliceridov, lipaze in/ali bilirubina v krvi.

In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.
Pri 1, 7% bolnikov z visokim krvnim tlakom z napredovalo diabetično ledvično boleznijo, ki so jih zdravili z irbesartanom, so opazili znižanje hemoglobina*, ki ni bilo klinično pomembno.

That treatment with Thelin often causes a decrease in haemoglobin and related red cell parameters o Need for full blood count prior to use and monitoring at clinically appropriate intervals.
Da zdravljenje s Thelinom pogosto povzroči znižanje hemoglobina in sorodnih parametrov rdečih krvnih celic o Pred začetkom jemanja je potrebno narediti krvno sliko in bolnika spremljati v klinično primernih intervalih.

That treatment with Volibris often causes a decrease in haemoglobin and haematocrit o Initiation of Volibris is not recommended for patients with clinically significant anaemia. o Patients taking Volibris should have their haemoglobin and/or haematocrit levels measured regularly. o If tests show a clinically significant decrease in haemoglobin or haematocrit, and other causes have been excluded, consider reducing the dose of Volibris, or stopping treatment.
Zdravljenje z zdravilom Volibris je pogosto povezano z znižanjem vrednosti hemoglobina in hematokrita o Pri bolnikih s klinično pomembno anemijo uvedba zdravljenja z zdravilom Volibris ni priporočljiva. o Pri bolnikih, ki jemljejo zdravilo Volibris, je treba redno nadzirati vrednosti hemoglobina in/ ali hematokrita. o Če preiskave pokažejo klinično pomembno znižanje vrednosti hemoglobina ali hematokrita in so drugi vzroki izključeni, je treba razmisliti o zmanjšanju odmerka zdravila Volibris ali o prekinitvi zdravljenja.

Major Fatal/Life-threatening Bleed: Clinically apparent withgt; 50 g/l decrease in haemoglobin or≥4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolaemic shock or severe hypotension requiring pressors or surgery.
Huda krvavitev s smrtnim izidom/smrtno nevarna krvavitev: Klinično opazna z znižanjem hemoglobinagt; 50 g/l ali transfuzijo ≥ 4 enot eritrocitov, ali s smrtnim izidom, ali intrakranialna, ali intraperikardialna s tamponado srca, ali s hipovolemičnim šokom ali hudo hipotenzijo, ki zahteva uporabo presorjev ali operacijo.

Decreases in haemoglobin and haematocrit, thrombocytopenia, leucopenia/ neutropenia, and cases of agranulocytosis or pancytopenia, have been reported very rarely.
Zelo redko so opažali zmanjšanje hemoglobina in hematokrita, trombocitopenijo, levkopenijo in nevtropenijo ter primere agranulocitoze ali pancitopenije.

Decreases in haemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment(see Table 3 and Table 7).
Znižanja hemoglobina, nevtrofilcev in trombocitov lahko zahtevajo zmanjšanje odmerka ali trajno ukinitev zdravljenja(glejte preglednico 3 in preglednico 7).

Among the 87 patients who were treated with Epclusa+ RBV for 12 weeks, decreases in haemoglobin to less than 10 g/dL and 8.5 g/dL during treatment were experienced by 23% and 7% patients, respectively.
Od 87 bolnikov, ki so prejemali zdravljenje z zdravilom Epclusa+ RBV 12 tednov, se je zmanjšanje ravni hemoglobina med zdravljenjem na manj kot 10 g/dl pojavilo pri 23% bolnikov, zmanjšanje na manj kot 8,5 g/dl pa pri 7% bolnikov.

Decreases in haemoglobin, white blood cells, platelets, neutrophils and increase in bilirubin may require dose reduction or permanent discontinuation from therapy(see section 4.2).
Zaradi zmanjšanja vrednosti hemoglobina, levkocitov, trombocitov in nevtrofilcev ter povečanja vrednosti bilirubina je lahko potrebno bodisi zmanjšanje odmerka ali pa trajna ukinitev terapije(glejte poglavje 4.2).

In eight placebo-controlled studies, clinically relevant decreases in haemoglobin(gt; 15% decrease from baseline resulting in values< 11 g/dl) were observed in 5.6% of bosentan-treated patients as compared with 2.6% of placebo-treated patients.
V osmih s placebom nadzorovanih študijah so opažali klinično pomembno znižanje hemoglobina(gt; 15% znižanje od izhodiščne vrednosti, kar je imelo za posledico vrednosti < 11 g/ dl) pri 5, 6% bolnikov, ki so jemali bosentan, in 2, 6% bolnikov, ki so prejemali placebo.